Experimental cell therapy aims to tame reckless immune system in brain diseases
Disease control
Recruiting now
This early-stage study is testing the safety and initial effectiveness of an experimental cell therapy called CNCT19. It is for adults with severe autoimmune diseases affecting the nervous system, like multiple sclerosis or myasthenia gravis, where standard treatments have failed…
Phase: EARLY_PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC